TFIP11: A Promising Drug Target and Biomarker for the Treatment of Inflammatory Neurodegenerative Diseases

Target Name: TFIP11

NCBI ID: G24144

TFIP11

TFIP11: A Promising Drug Target and Biomarker for the Treatment of Inflammatory Neurodegenerative Diseases

Introduction

Inflammatory neurodegenerative diseases, such as multiple sclerosis, rheumatoid arthritis, and fibromyalgia, are chronic conditions that cause significant morbidity and quality of life. These diseases are characterized by the persistent production of pro-inflammatory cytokines and chemokines, leading to the recruitment of immune cells to the site of injury or inflammation. The use of traditional therapeutic approaches often involves the use of disease-modifying drugs (DMDs), which aim to reduce inflammation and alleviate symptoms. However, the side effects of these drugs can be significant, and their long-term use is limited. Consequently, there is an ongoing need for new and more effective therapeutic approaches that can modulate inflammation without compromising on disease-modifying effects.

TFIP11, a novel gene that encodes a protein involved in the regulation of inflammation, has emerged as a promising drug target and biomarker for the treatment of inflammatory neurodegenerative diseases. In this article, we will discuss the biology of TFIP11, its potential as a drug target, and its potential as a biomarker for the diagnosis and prognosis of inflammatory neurodegenerative diseases.

The Biology of TFIP11

TFIP11 is a 21-kDa protein that is expressed in various tissues, including brain, heart, and muscle. It is a member of the transforming growth factor-11 (TGF-11) family, which includes several similar proteins that play important roles in cell growth, differentiation, and inflammation. TFIP11 is characterized by a N-terminal domain that contains a putative nuclear localization domain (pNLD), a C-terminal domain that contains a conserved Co-domain, and a unique N-terminal domain that contains a farnesylated cysteine 鈥嬧?媟esidue (CS) and a Glu-rich region (CSGlu21) that is involved in protein-protein interactions.

TFIP11 is involved in the regulation of inflammation by modulating the activity of several immune cell types, including T cells, B cells, and macrophages. It has been shown to regulate the production of pro-inflammatory cytokines, such as TNF-alpha, IL- 12, and IL-18, by interacting with the nuclear factor of activated T cells (NFAT). TFIP11 has also been shown to regulate the expression of anti-inflammatory cytokines, such as IL-10, by interacting with the transcription factor STAT3.

TFIP11 has been shown to have neuroprotective effects in several models of neurodegenerative diseases, including the treatment of experimental autoimmune encephalomyelitis (EAE) in mice. EAE is a model of multiple sclerosis that is characterized by the production of autoantibodies and the recruitment of immune cells to the central nervous system (CNS). Tfip11-deficient mice have been shown to have reduced disease severity and improved survival in EAE, suggesting that TFIP11 may be a potential therapeutic approach for the treatment of multiple sclerosis and other inflammatory neurodegenerative diseases.

Potential as a drug target

TFIP11 has been shown to have a high potential as a drug target for the treatment of inflammatory neurodegenerative diseases. Its ability to modulate the production of pro-inflammatory cytokines and its neuroprotective effects make it an attractive target for small molecule inhibitors. Several studies have shown that TFIP11 can be targeted by small molecules, including inhibitors of the pro-inflammatory pathway, such as those that target the transcription factor NFAT or the enzyme COX.

TFIP11 has also been shown to be a potential biomarker for

Protein Name: Tuftelin Interacting Protein 11

Functions: Involved in pre-mRNA splicing, specifically in spliceosome disassembly during late-stage splicing events. Intron turnover seems to proceed through reactions in two lariat-intron associated complexes termed Intron Large (IL) and Intron Small (IS). In cooperation with DHX15 seems to mediate the transition of the U2, U5 and U6 snRNP-containing IL complex to the snRNP-free IS complex leading to efficient debranching and turnover of excised introns. May play a role in the differentiation of ameloblasts and odontoblasts or in the forming of the enamel extracellular matrix

The "TFIP11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TFIP11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets